GC Famliy Site

cookie-layer close

COOKIE Setting

When you visit our website, information is stored in your browser or exported in the form of cookies.This information may be about you, your preferences, or the device you use, and is most often used to ensure that the website works properly. This information does not identify you directly, but it can offer a more optimized experience as you navigate our website. Because we respect your right to privacy, you may choose not to allow certain types of cookies. You can check the detailed settings and change them according to your needs.
Analytical cookies

These cookies collect information about how visitors use the website to help improve the site. For example, we anonymously collect information such as the visitor’s device, access area, and time of visit.

  • - Google Analytics (GA4)

    Lorem ipsum dolor sit amet consectetur adipisicing elitsumenda quia nesciunt quo aut soluta. Ipsa qui dolore minima odio facere?

img

Immuncell-LC

Product Immuncell-LC
img

Partnering to Advance
Liver Cancer Care

img
img

In hepatocellular carcinoma (HCC), the most common type of liver cancer, a significant number of patients are diagnosed in the early stage, providing the potential for a cure through ablation or resection. However, the lack of effective drugs to prevent HCC recurrence after resection underscores the critical need for potential adjuvant therapy options for this population.

  • Liver Cancer
  • 6thmost common cancer [1]
  • 1million +
  • global cases annually
  • About 30% of patient eligible for resection or transplantation[2]
  • 80% recurrence rates
  • in 5 year [3]
  • Clinical Unmet Needs High
  • : no approved therapy for
  • adjuvant setting[4]
  • [1]Llovet, J. M., Kelley, Hepatocellular carcinoma. Nature reviews. Disease primers, 7(1), 6.
  • [2]Spiros G Delis and Christos Dervenis. Selection criteria for liver resection in patients with hepatocellular carcinoma and chronic liver disease
  • [3]Duilio Pagano, Giuseppe Mamone, Ioannis Petridis & Salvatore Gruttadauria. (2022) Hepatocellular Carcinoma Recurrence: How to Manage
  • [4]NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Hepatocellular Carcinoma, Version 1.2023

The Only Approved HCC Adjuvant Therapy Globally

img
img
Product

Immunecell-LC (Autologous Cytokine Induced Killer Cells)

Indication

Adjuvant therapy for patients whose tumor has been removed after curative resection for hepatocellular carcinoma

Treatment Regimen for Immuncell-LC (16 cycles)
img

Immuncell-LC An Autologous Cell Therapy
with a Long-standing Track Record

Efficacy Data

Clinical Trial Phase 3 & 4 in HCC adjuvant
  • Recurrence-Free Survival
    Recurrence-Free Survival(RES) graph01
    Recurrence-Free Survival(RES) graph01
  • Overall Survival
    Overall Survival graph01
    Overall Survival graph01
  • Phase HR for RFS** HR for OS***
    Ph3 (3 yrs) 0.63 (P=0.010) 0.21 (P=0.008)
    Ph4 (Total 5 yrs) 0.67 (P=0.010) 0.33 (P=0.006)

    The 5 yrs follow-up starts with the enrollment of last patient.
    ** RFS: Recurrence Free Survival *** OS: Overall Survival

    Ref.1. Gastroenterology (2015) 148:1383-1391, 2. BMC Cancer (2019) 19:523 , NCT00699816

  • Overall Survival graph03
    Overall Survival graph03
Real World Data in HCC adjuvant
  • Recurrence-Free Survival
    Recurrence-Free Survival graph04
    Recurrence-Free Survival graph04
  • Real World Data
    Phase HR for RFS HR for OS
    Real World Data 0.42 (P=0.006) 0.30 (P=0.170)

    Real World Data was obtained from 118 patients

    • Phase 3 clinical trial:
      37%risk of recurrence
    • Real World Data:
      58%risk of recurrence
    Real World Data is better than Phase III clinical data

Safety Data

Highly safe and tolerable cell therapy with long-term follow-up data.

  • 10,000

    10,000 +

    of accumulated
    patients treated

  • 90

    up to 90 months

    of long-term
    follow-up data

  • No

    NOCytokine Release

    Syndrome or Immune effector Cell-Associated Neurotoxicity Syndrome

  • 0%

    0%Patients who

    delayed/stopped treatment due to serious adverse events
    (Grade 3 or 4)

Manufacturing Process

  • img
    img
    Sampling & Seperation
    Blood collection from patient
  • img
    img
    Expansion (Avg 14 days)
    Obtain multiple does with single blood draw
  • img
    img
    Quality Test
    Confirmation of cell stability and efficacy
  • img
    img
    I. V. Infusion
    The outpatient setting maximizes patient convenience

Insights into Immuncell-LC : Mechanism of Action

Dual Tumor Killing Effect by MHC Restricted & Unrestricted Cytotoxicity

  • 1

    The elimination of tumor cells occurs as CTL binds to MHC Class I via TCR.

  • 2

    CIK eliminates tumor cells lacking MHC Class I expression by interacting with NKG2D and NKG2D ligands present on the tumor cell surface.

  • Collectively, these cells efficiently eliminate tumor cells by preventing tumor cells from escaping immune surveillances

History

Immuncell -LC received South Korean MFDS approval for HCC immunotherapy in 2007 and
the US FDA’s Orphan Drug Designation for the treatment of liver cancer, brain, and pancreatic cancer.

  • 2007
    Approved curative
    adjuvant treatment for HCC
    in Korea
  • 2015
    Announcement of results of HCC phase III clinical trials
  • 2017
    Announcement of results of long-term follow-up phase III clinical trials
  • 2018
    Orphan drug designation for pancreatic cancer, liver cancer, Giloblastoma by FDA
  • 2019
    Published the Real World Data(HCC)
  • 2021
    Updated approval by newly established ATMP
    regulation in Korea
  • DISEASE
  • IMMUNCELL-LC
  • Efficacy & Safety
  • Manufacturing
  • Mechanism
  • History